Swiss pharma giant Novartis (NOVN: VX) has confirmed the effectiveness of its Ultibro Breezhaler (indacaterol/glycopyrronium bromide) over Seretide (salmeterol/fluticasone) in preventing chronic obstructive pulmonary disease (COPD) exacerbations.
The Ultibro Breezhaler is being marketed on behalf of Novartis’ alliance partner Vectura Group (LSE: VEC), the developer of the delivery system, while Seretide is licensed by UK pharma major GlaxoSmithKline (LSE: GSK).
Results from the head-to-head FLAME study have been published in the New England Journal of Medicine. They showed not only the once-daily Ultibro Breezhaler’s superiority over twice-daily Seretide in preventing COPD exacerbations, but also over the widely used inhaled corticosteroid (ICS)/LABA combination.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze